In the seven-plus years since Bayer closed its mammoth buyout of Monsanto, the combined company has struggled to contain ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

As Saudi Arabia strives to secure a spot for itself on the global biopharma scene, Germany’s Stada has become one of the ...

Only days after the surprise ouster of Sanofi CEO Paul Hudson, the executive roster shake-ups at the French drug giant are continuing with the appointment of a new specialty care chief. | Serving on ...

The “Hypertension Bites” initiative’s approach is inspired by ’90s reality TV, according to a launch announcement from the Hypertension Control Alliance, a coalition assembled by the CDC Foundation ...

The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

As Novo Nordisk’s hotly anticipated Wegovy pill gets off to the races in the U.S., the company is making sure to cover its ...

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...